Imidacloprid + Permethrin + Pyriproxyfen
545 adverse event reports submitted to the FDA
Active Ingredients
Administration Routes
Species Affected
Most Affected Breeds
Most Reported Reactions
Outcome Breakdown
Data Summary
| Metric | Value |
|---|---|
| Total adverse event reports | 545 |
| Reports involving death | 23 |
| Case-fatality rate (reported events) | 420.0% |
| Distinct species in reports | 3 |
| Distinct breeds in reports | 20 |
| Distinct reactions reported | 20 |
| Active ingredients on file | 4 |
Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.
Imidacloprid + Permethrin + Pyriproxyfen Adverse Event Insights
The FDA Center for Veterinary Medicine database currently holds 545 adverse event reports referencing Imidacloprid + Permethrin + Pyriproxyfen, including 23 reports in which the animal died — a 420.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredients on file: Imidacloprid, Imidacloprid + Permethrin + Pyriproxyfen, Permethrin, Pyriproxyfen. Reported administration routes include Topical, Unknown, Oral, Other. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.
The species most frequently named in Imidacloprid + Permethrin + Pyriproxyfen reports are Dog (529 reports), Cat (15 reports), Unknown (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (37), Dog (unknown) (31), Chihuahua (29) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.
The most commonly reported clinical signs associated with Imidacloprid + Permethrin + Pyriproxyfen are Lack of efficacy (ectoparasite) - flea (134), Pruritus (92), Vomiting (65), Lethargy (see also Central nervous system depression in 'Neurological') (61). Of the 545 reports with a coded outcome, Outcome Unknown is the leading category at 50.8%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Imidacloprid + Permethrin + Pyriproxyfen.
Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates
Read our methodology — how this data is sourced, computed, and verified.